Genome Editing

Editas Medicine to Present at Barclays Gene Editing & Gene | StockTitan.net | 11/9/2020

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing & Gene Therapy Summit on Monday, November 16 at 10:15am ET. The event will be webcast live and may be accessed on the Editas Medicine website in the Investors section. Archived recordings will be available for approximately 30 days following the event. About Editas Medicine As a leading genome editing company …

Editas Medicine (EDIT) Tops Q3 Earnings and Revenue Estimates - November 5, 2020 - Zacks.com | 11/5/2020

… to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 118.18%. A quarter ago, it was expected that this genome editing company would post a loss of $0.80 per share when it actually produced a loss of $0.43, delivering a surprise of 46.25%. Over the last four quarters, the company has surpassed consensus EPS estimates …

Follow Genome Editing:    

Emmanuelle Charpentier and Jennifer Doudna Sharpened Mother Nature’s Genetic Scissors and Won the Nobel for It | 11/3/2020

… with viruses by taking a snippet of the virus‚Äô genetic material and filing it away for later. Now, two women have won the 2020 Nobel Prize in Chemistry ‚Äúfor developing a method for genome editing ‚Äù . Emmanuelle Charpentier and Jennifer Doudna leveraged CRISPR into a pair of genetic scissors and showed how sharp they are by proving that they can edit any string of DNA this way. Since Emmanuelle …

Mammoth Scale: CRISPR Dx Company Partners with MilliporeSigma, Hamilton | 11/3/2020

Trevor Martin, PhD, Mammoth Biosciences co-founder and CEO Mammoth Biosciences√¢‚Ǩ‚Äùthe CRISPR-based diagnostics developer whose co-founders include Nobel laureate and genome editing pioneer Jennifer Doudna, PhD√¢‚Ǩ‚Äùplans to develop, scale-up, and commercialize its molecular diagnostic assay for COVID-19 through partnerships with MilliporeSigma and Hamilton. MilliporeSigma will serve as contract manufacturer for Mammoth√¢‚Ǩ‚Ñ¢s DETECTR BOOST SARS-CoV-2 Reagent Kit. Based …

Global Gene Editing Market Expected To Expand At Around 14.6% CAGR During 2020–2026 – ZMR | 11/2/2020

… was capitalized at around $4.02 billion in 2019 and is projected to reach about $7 billion by 2026, expanding at around 14.6% CAGR during the forecast period. The prominent players active in the global genome editing market include New England Biolabs, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA, GenScript Corporation, Sangamo Therapeutics, Inc., Editas Medicine, Integrated DNA Technologies, Lonza Group, Horizon Discovery Group, and OriGene Technologies. Rising Range Of Application …

Lesaffre and Recombia Biosciences to advance innovative gene editing technology through a strategic partnership | Markets Insider | Business Insider | 10/31/2020

PARIS and SAN FRANCISCO , Oct. 30, 2020 /PRNewswire/ – Recombia Biosciences announces the launch of operations in Brisbane, California . The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. A strong commitment to innovation With its partnership with Recombia, Lesaffre …

Study: There Is No Country Where Heritable Human Genome Editing Is Permitted | Forbes | 10/31/2020

In a new study , four researchers reviewed policy documents from 106 countries to map out the policy landscape regarding human germline and heritable genome editing, finding that only 11 countries explicitly allow the use of genetically modified in vitro embryos in laboratory research, and that no country allows for the use of such embryos to initiate pregnancies. The discussion around the social, ethical and policy implications of gene editing is …

Jury duty for global warming: citizen groups help solve the puzzle of climate action | 10/29/2020

… tackle another fraught science issue. Last month, he and other minipublic advocates published a call for what would be the first global citizens‚Äô assembly. He wants it to take on the issue of genome editing , on the grounds that its widespread ramifications demand international agreements. For this and many other science policy questions, he argues, minipublics are an excellent way to integrate public values with advice from scientists and …

Media alert: new articles in the CRISPR Journal | 10/25/2020

no comments IMAGE: The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing , and commentary and… view more Credit: Mary Ann Liebert, Inc., publishers The CRISPR Journal announces the publication of its October 2020 issue. The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and …

Media alert: new articles in the CRISPR Journal | 10/23/2020

IMAGE: The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing , and commentary and… view more Credit: Mary Ann Liebert, Inc., publishers The CRISPR Journal announces the publication of its October 2020 issue. The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing …

Study reveals restoration of retinal and visual function following gene therapy | 10/21/2020

… H. Leopold chair and a distinguished professor in the Gavin Herbert Eye Institute, Department of Ophthalmology at the UCI School of Medicine. “Our results demonstrate the most successful rescue of blindness to date using genome editing .” Inherited retinal diseases (IRDs) are a group of blinding conditions caused by mutations in more than 250 different genes. Previously, there was no avenue available for treating these devastating blinding diseases. Recently, the FDA …

Week in Review: Curon Bio Acquires Rights to Lymphoma Drug in $150 Million Deal | 10/17/2020

… financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. The company pledged to develop next-gen cancer immunotherapies for patients. China’s EdiGene raised $67 million in a Series B round to develop its genome editing technologies (see story ).The company is developing a portfolio of molecules aimed at genetic diseases and cancer, and it also offers drug discovery services using its CRISPR/Cas 9 proprietary high-throughput screening platforms …

The Nobel Prize in Chemistry 2020 | 10/16/2020

The Nobel Prize in Chemistry acknowledged a remarkable contribution in to health and medicine: Emmanuelle Charpentier and Jennifer A. Doudna received it for the development of a method for genome editing known as CRISPR. CRISPR has revolutionized all the life sciences, from plant breeding to genetic therapy. Charpentier is a French microbiologist, and Doudna is an American biochemist affiliated with UC Berkeley. In 2012, they were studying the immune system …

Project Research Scientist | 10/16/2020

… may have an important function for the development of these pluripotent cells. We seek to understand the function requirement of these factors using a range of methods including cutting-edge single cell, imaging and genome editing techniques. Ultimately, this knowledge will provide fundamental insights into human biology and facilitate the development of conditions for the further refinement of implantation models and the establishment of novel human stem cells and stem …

‘Personal Care Is Ripe for Disruption’: Providence to Acquire Simplura in $575M Deal | Home Health Care News | 10/15/2020

DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) – Precision BioSciences, Inc. (NASDAQ: DTIL ), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned by Precision. The patents …

‘Personal Care Is Ripe for Disruption’: Providence to Acquire Simplura in $575M Deal | Home Health Care News | 10/15/2020

DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) – Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned by Precision. The patents …

‘Personal Care Is Ripe for Disruption’: Providence to Acquire Simplura in $575M Deal | Home Health Care News | 10/15/2020

… ET Source: Precision Biosciences DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) – Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned …

‘Personal Care Is Ripe for Disruption’: Providence to Acquire Simplura in $575M Deal | Home Health Care News | 10/15/2020

… in Two Patent Interference Proceedings DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) – Precision BioSciences, Inc. ( DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned …

Nobel in Chemistry Honors CRISPR/Cas9 Genome Editing | 10/15/2020

The 2020 Nobel Prize in Chemistry has been awarded to Jennifer Doudna of the University of California, Berkeley and Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens, Berlin, Germany “for the development of a method for genome editing,” specifically the CRISPR/Cas9 genetic scissors. Using this tool, researchers can change the DNA of animals, plants and microorganisms with extremely high precision. This technology has had a …

Women in science celebrate Nobel Prize milestone, critique male-dominated STEM culture | 10/15/2020

For the first time in history, two women were awarded a joint Nobel Prize in chemistry on Oct. 7, 2020. Jennifer Doudna and Emmanuella Charpentier’s work on CRISPR, a revolutionary genome editing technology, demonstrates the inroads that women have made in the sciences—as well as the challenges that still exist. “It has a lot to do with the culture of science,” biology professor Amy Wilstermann said. “For many years …

Cas9-mediated Genome Editing Reveals a Significant Contribution of Calcium Signaling Pathways to Anhydrobiosis in Pv11 | 10/15/2020

New Results Cas9-mediated Genome Editing Reveals a Significant Contribution of Calcium Signaling Pathways to Anhydrobiosis in Pv11 View ORCID Profile Yugo Miyata , Hiroto Fuse , Shoko Tokumoto , Yusuke Hiki , Ruslan Deviatiiarov , Yuki Yoshida , Takahiro G. Yamada , Richard Cornette , Oleg Gusev , Elena Shagimardanova , Akira Funahashi , Takahiro Kikawada doi: https://doi.org/10.1101/2020.10.15.340281 Search for this author on this site Oleg Gusev 6 Extreme Biology laboratory, Institute of Fundamental Medicine and Biology, Kazan …

Sestina Bio Launches: Engineering Biology at the Level of Single Cells | PR Newswire | 10/15/2020

… organisms ‚Äî usually yeast and bacteria ‚Äî that produce new materials, fine and bulk chemicals, and pharmaceuticals, or which act as sensors that report on their environment. By combining new instruments for single cell genome editing , tools for single cell phenotyping, and closed-loop, machine learning-driven design and control of experiments, Sestina is developing the next generation of the automated synthetic biology toolkit. Sestina will harness these tools to …

Sestina Bio Launches: Engineering Biology at the Level of Single Cells | Markets Insider | Business Insider | 10/15/2020

… novel living organisms – usually yeast and bacteria – that produce new materials, fine and bulk chemicals, and pharmaceuticals, or which act as sensors that report on their environment. By combining new instruments for single cell genome editing , tools for single cell phenotyping, and closed-loop, machine learning-driven design and control of experiments, Sestina is developing the next generation of the automated synthetic biology toolkit. Sestina will harness these tools to …

The FAQs: What Christians Should Know About CRISPR Genetic Scissors | 10/14/2020

… Chemistry 2020 to Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens, Berlin, Germany and Jennifer A. Doudna of the University of California, Berkeley, for the development of a method for genome editing . According to the Nobel committee: Emmanuelle Charpentier and Jennifer A. Doudna have discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants …

Emmanuelle Charpentier and Jennifer A. Doudna Awarded 2020 Nobel Prize in Chemistry | 10/14/2020

On October 7, 2020, The Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry jointly to Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens and Jennifer A. Doudna of the University of California, Berkeley for the development of a method for genome editing . This method, the CRISPR-Cas9 genetic scissors, is one of gene technology’s sharpest tools. Modifying genes in cells used to be …

COVID-19

Mammoth Scale: CRISPR Dx Company Partners with MilliporeSigma, Hamilton | 11/3/2020

Trevor Martin, PhD, Mammoth Biosciences co-founder and CEO Mammoth Biosciences√¢‚Ǩ‚Äùthe CRISPR-based diagnostics developer whose co-founders include Nobel laureate and genome editing pioneer Jennifer Doudna, PhD√¢‚Ǩ‚Äùplans to develop, scale-up, and commercialize its molecular diagnostic assay for COVID-19 through partnerships with MilliporeSigma and Hamilton. MilliporeSigma will serve as contract manufacturer for Mammoth√¢‚Ǩ‚Ñ¢s DETECTR BOOST SARS-CoV-2 Reagent Kit. Based …

Medical Research

The FAQs: What Christians Should Know About CRISPR Genetic Scissors | 10/14/2020

… Pathogens, Berlin, Germany and Jennifer A. Doudna of the University of California, Berkeley, for the development of a method for genome editing. According to the Nobel committee: Emmanuelle Charpentier and Jennifer A. Doudna have discovered … scissors (hereafter, CRISPR) is a technology that enables geneticists and medical researchers to edit the genome of plants, animals, and humans. Genome editing (or gene editing) is a form of genome engineering in which DNA …

CRISPR

Editing Humanity | 10/13/2020

That is the new book by Kevin Davies, and the subtitle is The CRISPR Revolution and the New Era of Genome Editing . So far I am on p.74, but it is one of the best science books I have read in some while, maybe the best this year. Excerpt: …Cas9 normally takes about six hours to search through every PAM sequence in the bacterial genome, pausing at each prospective …

National Institutes of Health

As genome-editing trials become more common, informed consent is changing | 10/12/2020

As public interest and expanded research in human genome editing grows, many questions remain about ethical, legal and social implications of the technology. People who are seriously ill may overestimate the benefits of early clinical … the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, asked patients, parents and physicians in the sickle cell disease community what they wanted and needed to know about genome editing

Gene Therapy

2020 Nobel season opens with medicine prize | 10/6/2020

… also the author of several books, including the recently released “Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing.” What follows is a lightly edited transcript of our conversation, including brief portions … its medical potential. This is not the next version of gene therapy, where we just add a healthy gene to compensate for a broken gene or replace a broken gene. We’re actually going into cells …

Genomics

Nucleic Acid Isolation and Purification Market worth $4.8 billion by 2025 | 9/30/2020

… Urnov and Dirk Hockemeyer, implemented a so-called ”pop-up” testing lab in just three weeks. In tandem, the Innovative Genomics Institute (IGI) also created a platform to provide the campus community with asymptomatic testing … most notably famous for her pioneering work in CRISPR-based genome editing technologies. The effort is co-lead by Urnov, IGI’s Scientific Director of Technology and Translation, who also has an impressive career pushing the …

Regenerative Medicine

** | 9/29/2020**

Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees. Qihan was founded in 2018 to develop novel cell and organ therapies using multiplexable genome editing and …

NIH

** | 9/29/2020**

Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic … Advanced Research Projects Activity and the National Institutes of Health (NIH) BRAIN Projects, as well as the NIH Center for Excellence in Genomic Science. He has co-authored more than 515 papers and 130 patent …

Biotech

** | 9/29/2020**

Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees. Qihan was founded in 2018 to develop novel cell and organ therapies using multiplexable genome editing and …

Food and Drug Administration

Heavy lifting ahead if the U.S. is to do heritable genome editing - STAT | 9/4/2020

First Opinion The U.S. must do some heavy lifting to prepare for heritable genome editing By Josephine Johnston September 4, 2020 Reprints Adobe C ountries contemplating giving the green light to heritable genome editing received … and ethics of all applications of heritable editing . The U.S. Food and Drug Administration could assess the safety and effectiveness of this technology if it was authorized to do so, and institutional review boards could …

Big Pharma

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

… 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell … The drug is small-molecule PKC inhibitor licensed from Swiss Big Pharma Novartis. Now, and once more after a quiet period, it’s nabbed a new pact with GSK centered on its early-stage lethality programs …

CDC

U.S. Secretary of Agriculture Sonny Perdue and Pairwise Leaders Discuss Food Solutions to Health Challenges | Business Wire | 6/16/2020

… adults are getting the recommended daily allowance of fruits and vegetables, accordingly to the Centers for Disease Control and Prevention (CDC). Only eight percent of calories in the average U.S. diet come from fruit and … nutritious food on tables across North America. From developing novel genome editing tools to leveraging the natural genetic diversity of plants to creating robust partnerships and collaborations, Pairwise is addressing the biggest challenges facing the …

CAR-T

Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board | Business & Finance | heraldchronicle.com | Business Wire | 6/15/2020

… Within the collaboration Epsilen Bio will further develop the epigenetic silencing technology with the group of Epigenetic Regulation and Targeted Genome Editing led by Dr. Angelo Lombardo, and exclusively in-licensed by Epsilen Bio. The … S.A., a Nasdaq-listed clinical stage gene editing company developing CAR-T cell therapies for cancer, where she led business development as well as strategic planning. Dr. Simon is Chairman of the Board of Idorsia …

Precision Medicine

LabRoots’ Genetics Virtual Week Announces Three-Day Agenda for 2020 Event, Dedicated to Advancing Best Practices in Genomics, Molecular Diagnostics and Precision Medicine | PRWeb | 4/14/2020

… Genetics Virtual Week Announces Three-Day Agenda for 2020 Event, Dedicated to Advancing Best Practices in Genomics, Molecular Diagnostics and Precision Medicine Share Article GVW’s mission is to bring together innovators across healthcare and biomedical … look spanning three days with three core focuses, sessions comprise: Genome Editing The Evolution of Genome Reference Concepts Single Cell and Spatial Genomics Structural Variation Rare Disease in Precision Medicine Precision Medicine in Clinic Molecular …

Clinical Research

Is China Effectively Reforming Its Biotechnology Laws? | 12/6/2019

clinical research are coming into force, but do they mean real change for the country? New Rules as Part of China’s Biotechnology Strategy On top of Beijing’s existing prohibitions against reproductive human genome editing, the Chinese Health Ministry has published draft regulations outlining new criminal charges for genetically engineering humans. In April, the government further elevated the matter of human genetics to the high-water mark of fundamental rights, announcing …

UC Davis

CRISPR/CAS Gene Editing in Vivo Postdoctoral Position | Nature | 12/4/2019

… UC Davis) Davis, CA, United States Posted about 52 minutes ago Expires on January 21, 2020 Description: A postdoctoral position is available for a joint project between the laboratories of: Dr. Kit Lam ( https://basicscience.ucdmc.ucdavis.edu/Lam_Lab/ ), Dr. R. Holland Chang ( https://biology.ucdavis.edu/people/rholland-cheng ) Dr. David J. Segal ( https://biology.ucdavis.edu/people/david-segal ), supported by the NIH Somatic Cell Genome Editing consortium ( https://scge.mcw.edu/ ). The project will design …

Rice University

Why the paper on the CRISPR babies stayed secret for so long - MIT Technology Review | 12/3/2019

… last December, and his original team of 10 has scattered to the four winds. An American collaborator, Michael Deem of Rice University, is the subject of an investigation by that institution; it has come to … he’d prepared a scientific manuscript, titled “Birth of Twins After Genome Editing for HIV Resistance.” As he slept, he might have dreamed of being toasted for a medical first and seeing his name on a …

Clinical Data

New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells | Nature | 11/21/2019

… we employed a two-plasmid approach in order to achieve a beneficial and stable variant-specific correction using CRISPR/Cas9 genome editing. One plasmid carries a Donor DNA and a reporter system mCherry/GFP to … in males with an X-linked form of the disease. Clinical data and variants were submitted to the Leiden Open Variation Database LOVD, www.lovd.nl/COL4A5 (Individual ID 00245760). Patient 2 (3459/18ats) : The patient is affected …

Medicare

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA | STAT | 11/20/2019

… planting radioactive seeds meant to treat prostate cancer into veterans. Another controversy almost got MD Anderson kicked out of the Medicare program. The third left Hahn assuring his colleagues he did not racially target scientists … cells growing in lab dishes have found that CRISPR-based genome editing can alter DNA in ways that could raise the risk of cancer and other serious diseases — but, in all likelihood, not for years …

ISTH

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… whatever technology is best suited to deliver that treatment, including gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline … will recall that our last data follow-up was at ISTH in July 2019 where we showed data from the first four subjects at the high dose, 313, [indiscernible] had been followed for 24 weeks …

University of Missouri

Research team wants to eliminate dangerous plant diseases in rice | Phys Org | 10/28/2019

… bacterium to divide by preventing it from hijacking the plant’s resources as food supply ,” explains Dr. Bing Yang from the University of Missouri. To understand this, they used their knowledge of how the Xoo bacteria … y Broad-spectrum resistance to bacterial blight in rice using genome editing, Nature Biotechnology (2019). DOI: 10.1038/s41587-019-0267-z , https://nature.com/articles/s41587-019-0267-z Nature Biotechnology Provided by Heinrich-Heine University Duesseldorf Citation : Research team …

Georgia Tech

Genome Editing & Engineering Conference: 2-Day Event (San Diego, CA, United States - February 6-7, 2020) | Benzinga | 10/11/2019

4th Edition Genome Editing & Engineering Conference” conference Since past editions, we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool, gene expression, knock-in, genomic screening, along … of Laval, University of California, Center of Advanced Genome Engineering, Georgia Tech, Stanford University, Locana, Harvard Medical School, Agility, Poseida, Vertex, Ligandal, Integrated DNA Technologies, GE Healthcare, Cellecta, Agilent, Advanced Analytical, Thermofisher, Atum, Synthego, New …

Clinical Diagnostics

Analysis on the Global DNA Read, Write & Edit Market, 2017-2019 and Forecast to 2024 | PR Newswire | 10/10/2019

… delivered format, including sequencing workflow products (sample preparation kits and reagents, sequencing instruments and consumables, and informatics) and sequencing services (clinical diagnostics and sequencing services to applied market customers). The sequencing workflow products market is … of Multiple Testing Quality Assurance Initiative Pathology Project Somatic Cell Genome Editing Program Telomere-to-Telomere Consortium Trans Omics for Precision Medicine Initiative Population Sequencing Programs Chapter 6 DNA Read, Write and Edit Applications Applications …

Department of Health and Human Services

Molecular Combing to Be Used by NIH’s Scientists as a Tool for Cancer Research and Drug Screening | Business Wire | 9/25/2019

… biotechnology company developing molecular and Artificial Intelligence tools to control quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary molecular tools provide robust quantitative measurements … NIH), which is one of 11 agencies that comprise the Department of Health and Human Services (HHS). NCI, established under the National Cancer Institute Act of 1937, is the Federal Government’s principal agency for cancer …

Clinical Validation

The Alliance for Regenerative Medicine Releases Statement of Principles on Genome Editing | Globe Newswire | 8/27/2019

… The principles stated in the document are: 1. We endorse investigation of therapeutic applications of somatic cell gene editing: Regulated, clinical validation of somatic cell-based gene editing technologies for non-inherited genetic modification is … We recognize and support the ongoing work of the NIST Genome Editing Consortium, US Pharmacopeia, International Organization for Standardization (ISO), and other recognized standards development organizations to formulate gene editing standards that address key concepts …

Thermo Fisher Scientific

Global Gene Editing Market Expected To Expand At Around 14.6% CAGR During 2020–2026 – ZMR | 11/2/2020

genome editing market include New England Biolabs, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA, GenScript Corporation, Sangamo Therapeutics, Inc., Editas Medicine, Integrated DNA Technologies, Lonza Group, Horizon Discovery Group, and OriGene Technologies. Rising Range Of Application To Surge The Demand For Gene Editing In Coming Period The global gene editing market is expanding swiftly owing to its rising application in a huge range of domains, like therapeutics, agriculture biotechnology, and …

Allergan

Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer | Globe Newswire | 10/14/2020

… Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Alex Kelly has been appointed to the newly created … grow and continue to transform.” Alex joins Precision BioSciences from Allergan, where he was Executive Vice President, Corporate Affairs and Chief Communications Officer and President of The Allergan Foundation. In these roles, Alex developed internal …

Thermo Fisher

2020-2029 Report on Global CRISPR and CRISPR-Associated (Cas) Genes Market by Player, Region, Type, Application and Sales Channel | 9/22/2020

Thermo Fisher Scientific Horizon Discovery Group Intellia Therapeutics GE Healthcare Dharmacon Market split by Type, can be divided into: Genome Editing Genetic engineering gRNA Database/Gene Librar CRISPR Plasmid Human Stem Cells Genetically Modified Organisms/Crops Market split by Application, can be divided into: Biotechnology Companies Pharmaceutical Companies Academic Institutes Research and Development Institutes Market split by Sales Channel, can be divided into: Direct Channel Distribution Channel Market segment by …

Merck

Global CRISPR Cas9 Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread) | 9/16/2020

Merck GeneCopoeia CRISPR Therapeutics GenScript In Chapter 11 and 13.3, on the basis of types, the CRISPR Cas9 market from 2015 to 2026 is primarily split into: Genome Editing Genetic engineering gRNA Database/Gene Librar CRISPR Plasmid Human Stem Cells Genetically Modified Organisms/Crops Cell Line Engineering In Chapter 12 and 13.4, on the basis of applications, the CRISPR Cas9 market from 2015 to 2026 covers: Biotechnology Companies Pharmaceutical Companies …

Precision BioSciences

Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update | Globe Newswire | 8/13/2020

… Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced financial results for the second quarter ended June 30, 2020 and provided a business update. “We have continued to make important progress across our clinical portfolio, including the initiation of our Phase 1/2a study of BCMA-targeted PBCAR269A, bringing us to three CAR T candidates …

Beam Therapeutics

This Startup Might Finally Cure Sickle Cell Disease—After A Century Of Racist Neglect | Forbes | 7/10/2020

… blood disorder, which mostly affects Black people, is just one of thousands of rare diseases that could be cured by Beam Therapeutics’ revolutionary gene editing technology. B eam Therapeutics CEO John Evans loves rocket launches … the years ahead. “The stuff we can do now in genome editing would have seemed like magic five or ten years ago,” he says, as technological advancements suddenly have biotechs competing to cure rare genetic …

Gilead Sciences

Gilead axes $445M Precision Biosciences gene therapy hep B pact | FierceBiotech | 7/8/2020

Gilead Sciences is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact. Back in September 2018, Gilead laid up to $445 million on the table in biobucks that saw the pair collaborate on gene therapies aimed at eliminating viral infections in vivo by using Precision’s genome editing platform. Under the deal, Gilead was on tap to …

Gilead

Gilead axes $445M Precision Biosciences gene therapy hep B pact | FierceBiotech | 7/8/2020

Gilead Sciences is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact. Back in September 2018, Gilead laid up to $445 million on the table in biobucks that saw the pair collaborate on gene therapies aimed at eliminating viral infections in vivo by using Precision’s genome editing platform. Under the deal, Gilead was on tap to …

Sangamo Therapeutics

Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges | PR Newswire | 6/26/2020

… Inc, Cellectis, Applied StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck KGaA), DiaCarta, Editas Medicine, New England Biolabs, Sangamo Therapeutics, GenScript, Thermo Fisher Scientific Inc and CRISPR Therapeutics. Applied StemCell is a company … 3.8. Other Products 4. CRISPR Market Outlook - By Application 4.1. Genome Editing/Genetic Engineering 4.1.1. Genetically Modified Organisms 4.1.2. Agricultural Biotechnology 4.1.3. Other Genome Editing/Genetic Engineering 4.2. Grna Database/Gene Library 4.3. CRISPR Plasmid …

Intellia Therapeutics

Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges | PR Newswire | 6/26/2020

… are Horizon Discovery Ltd, Integrated DNA Technologies Inc, Caribou Biosciences Inc, Precision Biosciences, Lonza, Addgene, Origene Technologies Inc, Genedata AG, Intellia Therapeutics Inc, Cellectis, Applied StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck … 3.8. Other Products 4. CRISPR Market Outlook - By Application 4.1. Genome Editing/Genetic Engineering 4.1.1. Genetically Modified Organisms 4.1.2. Agricultural Biotechnology 4.1.3. Other Genome Editing/Genetic Engineering 4.2. Grna Database/Gene Library 4.3. CRISPR Plasmid …

Pfizer

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy | Business Wire | 6/18/2020

NEW YORK & BRISBANE, Calif.- Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 … therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com . About Pfizer Rare Disease Rare diseases include some of the most serious of …

Celgene

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

… 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell … already dotted with big names such as 5AM Ventures and Celgene. A year later, it wrapped up a $50 million IPO and later nabbed an FDA IND for its clinical effort IDE196, which is being …

Novartis

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

… 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell … is small-molecule PKC inhibitor licensed from Swiss Big Pharma Novartis. Now, and once more after a quiet period, it’s nabbed a new pact with GSK centered on its early-stage lethality programs MAT2A, Pol …

GlaxoSmithKline

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

As GlaxoSmithKline looks to deepen its cancer R&D, it’s penned an oncology development program with Ideaya Biosciences. South San Francisco-based Ideaya broke cover in 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell death. PARP inhibitors such as AstraZeneca’s Lynparza and Clovis …

AstraZeneca

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

As GlaxoSmithKline looks to deepen its cancer R&D, it’s penned an oncology development program with Ideaya Biosciences. South San Francisco-based Ideaya broke cover in 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell death. PARP inhibitors such as AstraZeneca’s Lynparza and Clovis …

LogicBio Therapeutics

LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders Nasdaq:LOGC | Globe Newswire | 6/5/2020

LEXINGTON, Mass., June 05, LogicBio Therapeutics, Inc. (Nasdaq: LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that its 2020 Annual Meeting of Stockholders (2020 Annual Meeting) will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19, and to support the health and well-being of our …

GSK

FiercePharmaAsia—CanSino’s COVID-19 vaccine data; Takeda’s new Alunbrig nod; GSK-Samsung deal | FiercePharma | 5/29/2020

… years. The deal will initially cover lupus drug Benlysta and could expand to other products. Possible candidates could come from GSK’s cancer pipeline, including the anti-BCMA antibody-drug conjugate belantamab mafodotin that’s under FDA … EdiGene pairs with Immunochina to develop CAR-T Therapy (release) Genome editing specialist EdiGene formed an R&D collaboration with Immunochina to develop CAR-T therapies for cancer. EdiGene has gene-editing platforms for hematopoietic …

Vertex Pharmaceuticals

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer | Globe Newswire | 4/30/2020

… efforts using stem-cell-derived pancreatic islets to cure type I diabetes starting in November 2018. Semma was acquired by Vertex Pharmaceuticals Inc., in October 2019. Prior to his role at Semma, Dr. Lebwohl held … leadership team as we propel the first systemic CRISPR/Cas9 genome editing treatment to the clinic this year,” said Dr. Lebwohl. “I am passionate about working on the next generation of treatments, like genome editing

Abbott Laboratories

Pre & Post COVID-19 Market Estimates-Global Biotechnology Reagents Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Agilent Technologies Inc. | Technavio | Business Wire | 4/18/2020

… availability of novel technologies such as highly personalized and predictive throughput screening, pre-disease and biomarker identification, gene therapy and genome editing for earlier disease detection, and rapid POC diagnostics is driving the demand for … get the third for free. Major Five Biotechnology Reagents Companies: Abbott Laboratories Abbott Laboratories has business operations under various segments, such as established pharmaceuticals products, nutritional products, diagnostic products, and medical devices. The company’s key …

Qiagen

2020 Agricultural Biotechnology Market Study, Featuring Profiles of 96 Companies Including Ajinomoto, BASF, Cibus, Novozymes, Oxford Nanopore Technologies, and Qiagen | PR Newswire | 3/25/2020

2020 Agricultural Biotechnology Market Study, Featuring Profiles of 96 Companies Including Ajinomoto, BASF, Cibus, Novozymes, Oxford Nanopore Technologies, and Qiagen News provided by Mar 25, 2020, 12:15 ET Share this article DUBLIN , March 25, 2020 … generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools, and assaying their role in enhancing the marketplace Underlying market opportunities for biotechnology tools, genomic-enabled products, and biotech seeds enhancing growth …

GE Healthcare

CRISPR & CRISPR-associated (Cas) Genes Market Outlook to 2027 | GE Healthcare, Koninklijke Philips N.V., Cardinal Health, Halma, MasimoHillrom Holdings | 12/2/2019

… GE Healthcare, Koninklijke Philips N.V., Cardinal Health, Halma, MasimoHillrom Holdings The report on “CRISPR & CRISPR-associated (Cas) Genes Market” will help Major Players and the new entrants to understand scrutinize the market in detail. This information will encourage the Major Players to decide their business strategy and achieve proposed business aims. CRISPR and CRISPR-Associated (Cas) Genes is a genome editing tool that enables the researchers to make changes in …

Regeneron Pharmaceuticals

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Intrexon

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Spark Therapeutics

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Biogen

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Morgan Stanley

Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares Nasdaq:EDIT | Globe Newswire | 6/26/2020

CAMBRIDGE, Mass., Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the closing of its previously announced underwritten offering of 6,900,000 shares of its common stock at a public offering price of … the shares in the offering were sold by Editas Medicine. Morgan Stanley acted as sole book-running manager for the offering. A registration statement on Form S-3 (including a preliminary prospectus describing the terms …

Editas Medicine Announces Pricing of Offering of Common Stock | Globe Newswire | 6/24/2020

CAMBRIDGE, Mass., June 23, Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 6,000,000 shares of its common stock at a public offering price of … or about June 26, 2020, subject to customary closing conditions. Morgan Stanley is acting as sole book-running manager for the offering. A registration statement on Form S-3 (including a preliminary prospectus describing the …

Zacks Equity Research

Editas’ (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y | Zacks | 5/8/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Editas Medicine, Inc. ( EDIT - Free Report ) incurred a loss … option agreement with Sandhill Therapeutics, Inc., to combine their respective genome editing and cell therapy technologies for discovering and developing allogeneic engineered NKcells and non-alpha beta T cell medicines to treat cancer. Editas Medicine …

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates | Zacks | 11/12/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Editas Medicine ( EDIT - Free Report ) came out … of 9.59%. A quarter ago, it was expected that this genome editing company would post a loss of $0.59 per share when it actually produced a loss of $0.69, delivering a surprise of -16.95%. Over …

Guggenheim Securities

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… Head of Corporate Strategy Sung Lee - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Gena Wang - Barclays Whitney Ijem - Guggenheim Securities Ritu Baral - Cowen Eric Joseph - JPMorgan Yanan Zhu - Wells Fargo Securities Operator Good … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline of genomic medicines across these various platforms, we understand that …

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/9/2019

… Ed Conner - Chief Medical Officer Ed Rebar - Chief Technology Officer Kathy Yi - Chief Financial Officer Conference Call Participants Evan Wang - Guggenheim Securities Xiaobin Gao - Barclays Ritu Baral - Cowen Yanan Zhu - Wells Fargo Securities Jim Birchenough … medicines pipeline encompasses four complementary approaches, gene therapy, ex vivo genome editing and gene regulation. We are developing products for conditions for the suite of proprietary genomic medicine technologies has the potential to make a …

NCI

Molecular Combing to Be Used by NIH’s Scientists as a Tool for Cancer Research and Drug Screening – Company Announcement - FT.com | Financial Times | 9/25/2019

… modified genome, announce the acquisition of the molecular combing platform by the Developmental Therapeutics Branch at the National Cancer Institute (NCI) within the NIH based in Bethesda. The FiberComb ® and FiberVision ® are going to be … quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary molecular tools provide robust quantitative measurements that are needed to enable high confidence characterization of DNA …

Molecular Combing to Be Used by NIH’s Scientists as a Tool for Cancer Research and Drug Screening | Business Wire | 9/25/2019

… modified genome, announce the acquisition of the molecular combing platform by the Developmental Therapeutics Branch at the National Cancer Institute (NCI) within the NIH based in Bethesda. The FiberComb ® and FiberVision ® are going to be … quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary molecular tools provide robust quantitative measurements that are needed to enable high confidence characterization of DNA …

Oxford Finance

SGI-DNA Secures $25 Million Series A Financing to Support Commercial Launch | Business Wire | 9/9/2019

… DNA data storage solutions, has completed a $25 million Series A financing round led by Northpond Ventures, with participation from Oxford Finance and BroadOak Capital Partners. Proceeds of the financing will support the global commercial … engineering, synthesis of biological libraries for drug discovery, and CRISPR genome editing. Simply put, what used to take up to six weeks can now be performed within a few hours and with only the push …

SGI-DNA Secures $25 Million Series A Financing to Support Commercial Launch | Business & Finance | heraldchronicle.com | Business Wire | 9/9/2019

… DNA data storage solutions, has completed a $25 million Series A financing round led by Northpond Ventures, with participation from Oxford Finance and BroadOak Capital Partners. Proceeds of the financing will support the global commercial … engineering, synthesis of biological libraries for drug discovery, and CRISPR genome editing. Simply put, what used to take up to six weeks can now be performed within a few hours and with only the push …

Leerink Partners

Intellia Therapeutics Announces Pricing Of Public Offering Of Common Stock - TheStreet | 11/2/2017

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) – Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an … to be sold by Intellia. Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers of the offering. The offering is expected to close on or about November 6, 2017, subject …

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock | CNBC | 11/2/2017

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) – Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an … to be sold by Intellia. Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers of the offering. The offering is expected to close on or about November 6, 2017, subject …

Moffitt Cancer Center

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate | Globe Newswire | 12/9/2019

… event today starting at 8:15 p.m. ET, with live webcast available online- DURHAM, N.C., Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS … pharmaceutical company. Data will be presented by Bijal Shah, MD, Moffitt Cancer Center, at the 61 st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, during a poster session from 6:00-8:00 …

Johns Hopkins University School of Medicine

Genome Editing Services Market-Focus on CRISPR, 2019-2030 | PR Newswire | 11/28/2019

Genome Editing Services Market-Focus on CRISPR, 2019-2030 News provided by Nov 28, 2019, 08:00 ET NEW YORK , Nov. 28, 2019 /PRNewswire/ – INTRODUCTION The 1970s witnessed the introduction of one of the most revolutionary advances in biotechnology, when Hamilton Smith (a molecular biologist at Johns Hopkins University School of Medicine ) purified the first site-specific restriction enzyme , called Hind II. This development enabled the scientific community to devise the means …

University of Texas MD Anderson Cancer Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Leiden University Medical Center

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

Silvère M van der Maarel 1 1 Human Genetics , Leiden University Medical Center , Leiden , The Netherlands 2 Hubrecht Institute-KNAW and University Medical Center , Utrecht , The Netherlands 3 Clinical Sciences of Companion Animals , Faculty of … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

Fred Hutchinson Cancer Research Center, Seattle WA

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

… The Netherlands 6 Center for Human and Clinical Genetics , Leiden University Medical Center , Leiden , The Netherlands 7 Division of Biology , Fred Hutchinson Cancer Research Center , Seattle , Washington , USA 8 Peripheral Nervous System, Muscle and ALS … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

MD Anderson Cancer Center

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA | STAT | 11/20/2019

… Nicholas Florko @NicholasFlorko November 20, 2019 Dr. Stephen Hahn, President Trump’s nominee to lead the FDA The University of Texas MD Anderson Cancer Center S tephen Hahn, President Trump’s nominee to helm the Food and … cells growing in lab dishes have found that CRISPR-based genome editing can alter DNA in ways that could raise the risk of cancer and other serious diseases — but, in all likelihood, not for years …

Massachusetts General Hospital

Putting one foot in front of the other | Nature | 11/8/2019

Massachusetts General Hospital (MGH). At the MGH, I utilised CRISPR-Cas9 genome editing technology to recapitulate human craniofacial anomalies in the zebrafish model organism. “I enjoy pushing my mind and body to try and exceed my limits. It’s not often that I will say no to a new challenge if I feel that I can be passionate about it and give it my 100% effort.” At Michigan, the DDS/PhD …

Harvard Medical School

Genome editing of HBG1 and HBG2 to induce fetal hemoglobin | Blood Advances | American Society of Hematology | 11/6/2019

GENE THERAPY November 6, 2019 Genome editing of HBG1 and HBG2 to induce fetal hemoglobin Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN; Search for other works by this author on: Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA; 3 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; 4 Department of Pediatrics, Harvard Medical School, Boston, MA; 5 Harvard Stem Cell Institute, Cambridge, MA; 6 …

University of Rochester

Laboratory Technician IV (S) - 211587 - Rochester, NY, , USA #jobs #Rochester pls RT | 10/30/2019

Job Detail for Laboratory Technician IV (S) - 211587 Job Location: University of Rochester, Rochester, NY, , USA Job Detail for Laboratory Technician IV (S) - 211587 Job Location: University of Rochester, Rochester, NY, , USA Jobs In Laboratory … is responsible for supporting mouse model generation in the Mouse Genome Editing Resource (MGE) core facility. He or she will carry out sophisticated experiments in mouse colony management and mouse genetic manipulation. Responsibilities: Under general …

Children's Hospital of Philadelphia

ASGCT Presents Career Development Awards to Six Members | PRWeb | 10/23/2019

… of non-viral mechanisms of targeting lung epithelial cells for prenatal gene editing in a large animal model Christopher Nelson, Ph.D.—assistant professor, University of Arkansas Characterizing and overcoming the host response to genome editing therapy Kalpana Parvathaneni, MS, Ph.D.— postdoctoral researcher, Center for Cellular Immunotherapies, University of Pennsylvania Engineered CAR-T Cells to Overcome Alloimmunity in Transplant Rejection ASGCT is honored to have received such strong interest from its …

Children's Hospital Oakland, Oakland CA

Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium | PR Newswire | 2/7/2018

Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium News provided by 19:30 ET Share this article RICHMOND, Calif., Feb. Sangamo Therapeutics, Inc. (Nasdaq: SGMO ) today announced the … principal investigator for the CHAMPIONS study at the UCSF Benioff Children’s Hospital Oakland, where the first subjects in the study were treated. Dr. Edward Conner , Chief Medical Officer of Sangamo, also commented: “We are pleased …

Tenet Healthcare Corporation

mHealth and Telemedicine Innovation Vastly Improving Healthcare Services for Patients | PR Newswire | 11/9/2017

… include: Reliq Health Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Editas Medicine, Inc. (NASDAQ: EDIT), Tenet Healthcare Corporation (NYSE: THC), Array BioPharma Inc. (NASDAQ: ARRY ). Reliq Health Technologies Inc. (OTCQB … Healthcare Industry developments: Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, the week reported financial results for the third quarter ended September 30, 2017 , and provided an update on recent achievements and upcoming …

Jennifer Doudna

Emmanuelle Charpentier and Jennifer Doudna Sharpened Mother Nature’s Genetic Scissors and Won the Nobel for It | 11/3/2020

… genome editing‚Äù . Emmanuelle Charpentier and Jennifer Doudna leveraged CRISPR into a pair of genetic scissors and showed how sharp they are by proving that they can edit any string of DNA this way. Since Emmanuelle and Jennifer published their 2012 paper on CRISPR/Cas9 , researchers have used these genetic scissors to create drought-resistant plants and look for new gene-based cancer therapies. Researchers are also hoping to use …

Emmanuelle Charpentier

Jennifer Doudna Awarded 2020 Nobel Prize in Chemistry | 10/12/2020

Previous Next Newswise — The discovery of genetic scissors known as CRISPR-Cas9 has earned two scientists the 2020 Nobel Prize in Chemistry. Jennifer Doudna , a Howard Hughes Medical Institute (HHMI) Investigator at University of California, Berkeley, and Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens are being honored for the development of a method for genome editing , the Royal Swedish Academy of Sciences announced today. Their …

David Li

Nobel Prize for chemistry awarded to Charpentier and Doudna | Phys Org | 10/7/2020

… Emmanuelle Charpentier and American Jennifer A. Doudna have won the Nobel Prize 2020 in chemistry for developing a method of genome editing likened to ‘molecular scissors’ that offer the promise of one day curing genetic … on Twitter to the winners. Another Broad gene editing scientist, David Liu, noted on Twitter that the winners’ seminal research paper in 2012 has been cited more than 9,500 times, or about once every eight …

He Jiankui

Nobel Prize for chemistry awarded to Charpentier and Doudna | Phys Org | 10/7/2020

genome editing likened to ‘molecular scissors’ that offer the promise of one day curing genetic diseases. (AP Photo/Markus Schreiber) Much of the world became aware of CRISPR in 2018, when Chinese scientist He Jiankui revealed he had helped make the world’s first gene-edited babies, to try to engineer resistance to infection with the AIDS virus. His work was denounced as unsafe human experimentation, and he has been sentenced …

David Liu

Nobel Prize for chemistry awarded to Charpentier and Doudna | Phys Org | 10/7/2020

… Emmanuelle Charpentier and American Jennifer A. Doudna have won the Nobel Prize 2020 in chemistry for developing a method of genome editing likened to ‘molecular scissors’ that offer the promise of one day curing genetic … on Twitter to the winners. Another Broad gene editing scientist, David Liu, noted on Twitter that the winners’ seminal research paper in 2012 has been cited more than 9,500 times, or about once every eight …

Feng Zhang

CRISPR, the revolutionary genetic “scissors,” honored by Chemistry Nobel | 10/7/2020

… the Science of Pathogens and Jennifer Doudna of the University of California, Berkeley, “for the development of a method for genome editing.” They first showed that CRISPR—which stands for clustered regularly interspaced short palindromic … products, and ways to control pests. Many scientists anticipated that Feng Zhang of the Broad Institute, who showed 6 months later that CRISPR worked in mammalian cells, would share the prize. The institutions of the …

George Church

2020 Nobel season opens with medicine prize | 10/6/2020

… also the author of several books, including the recently released “Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing.” What follows is a lightly edited transcript of our conversation, including brief portions … other spheres of medicine. One of the companies launched by George Church, an outsized figure in genetics and a prominent figure in the book, is called eGenesis. They’re based in Cambridge, Massachusetts. They are engineering …

Benson Hill

Benson Hill Awarded AI-based Solution of the Year Honors at AgTech Breakthrough Awards | PR Newswire | 9/10/2020

ST. LOUIS , Sept. 10, Benson Hill , a crop improvement company dedicated to unlocking the natural genetic diversity of plants, announced today it has been awarded ‘AI-based AgTech Solution of the Year’ at the AgTech … CropOS™ platform combines machine learning and big data analytics with genome editing and plant biology to drastically accelerate and simplify the product development process,” said Jason Bull , Chief Technology Officer of Benson Hill . “This leading …

Matt Kane

Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update | Globe Newswire | 8/13/2020

… Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced financial results for the second quarter ended June 30, 2020 … ALL, no earlier than the fourth quarter of 2020,” said Matt Kane, CEO and co-founder of Precision BioSciences. “Our pre-clinical work also continued to progress, including our lead gene correction program targeting PH1 …

Tom Adams

U.S. Secretary of Agriculture Sonny Perdue and Pairwise Leaders Discuss Food Solutions to Health Challenges | Business Wire | 6/16/2020

… helping create opportunities for improvement. “Now more than ever, consumers need better options for healthier food choices,” said Pairwise CEO Tom Adams. “We are grateful for the opportunity to discuss with Secretary Perdue and Commissioner … nutritious food on tables across North America. From developing novel genome editing tools to leveraging the natural genetic diversity of plants to creating robust partnerships and collaborations, Pairwise is addressing the biggest challenges facing the …

Charles Albright

Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies | Globe Newswire | 5/15/2020

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) – Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its … make a meaningful impact in the treatment of cancer,” said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “We are focused on solid tumors given the high unmet need and will …

John Leonard

Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy | Globe Newswire | 5/12/2020

… in non-human primate study for our newest development candidate, NTLA-2002 CAMBRIDGE, Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo … with NTLA-5001 next year,” said Intellia President and CEO John Leonard, M.D. “We are also pleased to present data that support our recently announced HAE development candidate, NTLA-2002, Intellia’s second systemic therapy employing …

Fred Chereau

LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates | Globe Newswire | 5/12/2020

LEXINGTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) – LogicBio Therapeutics, Inc. (Nasdaq: LOGC ) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial … trial for LB-001 after we complete these interactions,” said Fred Chereau, CEO of LogicBio. “At the same time, we continue to advance our research programs and look forward to sharing the fruits of our …

Udit Batra

MilliporeSigma Granted U.S. Patents for Foundational CRISPR-Cas9 Technology | PR Newswire | 5/11/2020

… other uses - Committed to ethical use of genome-editing technology BURLINGTON, Mass. , May 11, 2020 /PRNewswire/ – MilliporeSigma , a leader in genome editing, today announced that two of its CRISPR-Cas9-assisted genome-editing patents have … applications and can be used to develop personalized therapies,” said Udit Batra , CEO, MilliporeSigma. “As a leading innovator of CRISPR technology, we will license this technology to ensure that the full potential of this powerful …

David Thom

Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources | Globe Newswire | 4/15/2020

… BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® genome editing platform, today announced that Dora Alvarado has joined the leadership team as Senior … continue our growth in cell therapy and gene editing,” commented David Thomson, PhD, Chief Operating Officer of Precision BioSciences. Ms. Alvarado joins Precision BioSciences with more than 25 years of experience developing and leading high …

Bijal Shah

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate | Globe Newswire | 12/9/2019

… event today starting at 8:15 p.m. ET, with live webcast available online- DURHAM, N.C., Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS … Servier, an international pharmaceutical company. Data will be presented by Bijal Shah, MD, Moffitt Cancer Center, at the 61 st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, during a poster …

Fred Hutchinson

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

… The Netherlands 6 Center for Human and Clinical Genetics , Leiden University Medical Center , Leiden , The Netherlands 7 Division of Biology , Fred Hutchinson Cancer Research Center , Seattle , Washington , USA 8 Peripheral Nervous System, Muscle and ALS … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

Katrine Bosley

Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors | Business Wire | 11/21/2019

… the discovery of a new class of small-molecule medicines that directly target RNA, announced today that it has appointed Katrine Bosley as Chairman of its Board of Directors. Ms. Bosley is a proven biotechnology … VP Business Development) and developed innovative products and technologies (CRISPR genome editing, Tysabri (natalizumab), covalent drugs). Her experiences include Chairing the Emerging Companies Section of the Board of BIO; serving as the Entrepreneur-in-Residence …

Denis Rebrikov

Human germline editing needs one message | Nature | 11/20/2019

… in China whose genomes had been edited to prevent HIV infection. Undeterred by the global opprobrium heaped on He, Russia’s Denis Rebrikov told Nature last month about more experiments involving gene editing of human eggs … the blueprint of life. Read the paper: Search-and-replace genome editing without double-strand breaks or donor DNA The speed of technological advance, coupled with some scientists’ determination to press ahead with editing human …

Adam Feuerstein

First CRISPR treatment for blood diseases shows early benefits in two patients | STAT | 11/19/2019

Biotech First CRISPR treatment for blood diseases shows early benefits in two patients By Sharon Begley @sxbegle and Adam Feuerstein @adamfeuerstein November 19, 2019 Red blood cells from a person with sickle cell disease. Jonathan … relatively short time, but the encouraging data offer hope that genome editing might one day offer a safe, durable cure for both blood diseases. The companies, CRISPR Therapeutics ( CRSP ) and Vertex ( VRTX ) Pharmaceuticals, have competition …

Adrian Woolfson

Sangamo Therapeutics Announces New Scientific Advisory Board | Business Wire | 11/8/2019

… identify new opportunities for differentiation and innovation in the genomic medicine space, and to define and address future trends,” said Adrian Woolfson, B.M., B.Ch., Ph.D., Head of Research and Development. “As Sangamo continues to advance … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit www.sangamo.com . Forward-Looking Statements This press release contains forward-looking statements regarding Sangamo’s current …

Dwayne Dundore

$YGYI Granted Registered Hemp Seed Dealer License in the State of Florida | 11/8/2019

… housed with dehumidification systems and will be located on our 45-acre tract of land in Central Florida,” said Dr. Dwayne Dundore, President of Khrysos. “We are proud to be granted this Seed Dealer License … this division of our company. We believe his expertise in genome editing, tissue culture production, clonal propagation, and seed production provides us with an opportunity to take a leading role in the Hemp Industry.” About …

Sandy Macrae

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… 2019 Earnings Conference Call November 6, 2019 5:00 PM ET Company Participants McDavid Stilwell - Vice President-Corporate Communications & Investor Relations Sandy Macrae - Chief Executive Officer Adrian Woolfson - Head of Research & Development Bettina Cockroft - Chief Medical … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline of genomic medicines across these various platforms, we understand that …

Ritu Baral

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… Corporate Strategy Sung Lee - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Gena Wang - Barclays Whitney Ijem - Guggenheim Securities Ritu Baral - Cowen Eric Joseph - JPMorgan Yanan Zhu - Wells Fargo Securities Operator Good afternoon, and … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline of genomic medicines across these various platforms, we understand that …

Michel Sadelain

CRISPR Approach To Fighting Cancer Called ‘Promising’ In 1st Safety Test | 11/7/2019

genome editing in patients and shows the potential of this technology to be a safe and effective therapy,” Doudna says. Dr. Michel Sadelain , who is doing related research at Memorial Sloan Kettering Cancer Center in New York, says he’s glad to see the editing of genes move into the clinic this way, though he stresses that patients will have to be followed much longer to gain confidence that the approach …

State of California

Lesaffre and Recombia Biosciences to advance innovative gene editing technology through a strategic partnership | Markets Insider | Business Insider | 10/31/2020

PARIS and SAN FRANCISCO , Oct. 30, 2020 /PRNewswire/ – Recombia Biosciences announces the launch of operations in Brisbane, California . The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. A strong commitment to innovation With its partnership with Recombia, Lesaffre …

State of North Carolina

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma | Globe Newswire | 6/8/2020

… Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced that the first patient has been dosed in a Phase … in-house Manufacturing Center for Advanced Therapeutics (MCAT) in Durham, North Carolina. PBCAR269A has received Orphan Drug Designation from the FDA for the treatment of multiple myeloma. About the PBCAR269A Clinical Trial PBCAR269A is being …

Berkeley, California

The FAQs: What Christians Should Know About CRISPR Genetic Scissors | 10/14/2020

What just happened? Last week the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry 2020 to Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens, Berlin, Germany and Jennifer A. Doudna of the University of California, Berkeley, for the development of a method for genome editing. According to the Nobel committee: Emmanuelle Charpentier and Jennifer A. Doudna have discovered one of gene technology’s sharpest …

State of Massachusetts

2020 Nobel season opens with medicine prize | 10/6/2020

… also the author of several books, including the recently released “Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing.” What follows is a lightly edited transcript of our conversation, including brief portions … and in Europe and at the Broad Institute in Cambridge, Massachusetts. These papers really put in the hands of researchers a tool that is widely available, easy to use, requires no expensive equipment, and gives …

Durham, North Carolina

Recent Investment Analysts’ Ratings Updates for Precision BioSciences (DTIL) | 6/19/2020

genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. “ 6/1/2020 – Precision BioSciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Precision BioSciences, Inc …

New York, New York

Global Gene Editing Market Expected To Expand At Around 14.6% CAGR During 2020–2026 – ZMR | 11/2/2020

… New York, United States - November 2, 2020 /MarketersMedia/ ‚Äî As per the analysts at Zion Market Research, the global gene editing market was capitalized at around $4.02 billion in 2019 and is projected to reach about $7 billion by 2026, expanding at around 14.6% CAGR during the forecast period. The prominent players active in the global genome editing market include New England Biolabs, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA …

York, Pennsylvania

Global Gene Editing Market Expected To Expand At Around 14.6% CAGR During 2020–2026 – ZMR | 11/2/2020

… York, United States - November 2, 2020 /MarketersMedia/ ‚Äî As per the analysts at Zion Market Research, the global gene editing market was capitalized at around $4.02 billion in 2019 and is projected to reach about $7 billion by 2026, expanding at around 14.6% CAGR during the forecast period. The prominent players active in the global genome editing market include New England Biolabs, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA, GenScript …

State of New York

Global Gene Editing Market Expected To Expand At Around 14.6% CAGR During 2020–2026 – ZMR | 11/2/2020

… New York, United States - November 2, 2020 /MarketersMedia/ ‚Äî As per the analysts at Zion Market Research, the global gene editing market was capitalized at around $4.02 billion in 2019 and is projected to reach about $7 billion by 2026, expanding at around 14.6% CAGR during the forecast period. The prominent players active in the global genome editing market include New England Biolabs, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA …

Cambridge, Massachusetts

Nobel Prize in Chemistry Is Awarded for Gene-Editing Technologies - WSJ | The Wall Street Journal | 10/7/2020

Two scientists won the Nobel Prize in Chemistry on Wednesday for discovering a powerful tool for genome editing that has enabled relatively quick and easy modification of the building blocks of life and promises new … patent dispute in the U.S. between the Broad Institute in Cambridge, Mass., and the University of California, Berkeley and partner institutions. The Broad Institute of MIT and Harvard was issued U.S. patents for the technology …

Los Angeles, California

Nonviral Genetic Engineering of CAR T Cells | 6/25/2020

… of California, San Francisco, who has been pursuing the use of ribonucleoprotein (RNP) electroporation 2 and nonviral DNA templates for genome editing 3 in immune cells. “A drawback of virus is that its production is … Chen, PhD, an associate professor at the University of California, Los Angeles, and a member researcher of the Parker Institute for Cancer Immunotherapy. Consequently, the high manufacturing costs and safety concerns of viral vectors have …

Boston, Massachusetts

Week in Review: Curon Bio Acquires Rights to Lymphoma Drug in $150 Million Deal | 10/17/2020

genome editing technologies (see story ).The company is developing a portfolio of molecules aimed at genetic diseases and cancer, and it also offers drug discovery services using its CRISPR/Cas 9 proprietary high-throughput screening platforms. Founded in 2015, EdiGene is headquartered in Beijing and Boston . The company said it would use the proceeds to advance its drug candidates into clinical trials. ImmuneOnco, a Shanghai oncology immunotherapy company, completed a …

Chapel Hill, North Carolina

Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone | 5/27/2020

… PLoS Genet 16(5): e1008770. https://doi.org/10.1371/journal.pgen.1008770 Editor: Gregory P. Copenhaver, The University of North Carolina at Chapel Hill, UNITED STATES Received: October 24, 2019; Accepted: April 8, 2020; Published: May 26 … fraction of T3-regulated enhancers lacking TRBS. Using CRISPR-mediated genome editing it has previously been shown that deletion of a specific enhancer can lead to reduced H3K27Ac of interacting enhancers [ 63 ], suggesting possible functional …

State of Minnesota

Precision genome editing enters the modern era | Phys Org | 6/15/2020

CRISPR has sparked a renaissance in genome editing. Now, next-generation CRISPR technologies let scientists modify the genome more efficiently and precisely than before. Such tools could one day serve as therapeutics, but many challenges … says Reuben Harris, an HHMI Investigator at the University of Minnesota, who helped organize the January conference. “It triggered a landslide in this area.” Today, scientists have published more than 300 papers on the technique …